Form 4: Trevi Therapeutics Director Acquires Stock Options

Trevi Therapeutics, Inc. reports that Director Anne Vanlent was granted stock options for 35,000 shares.

Summary

• Anne Vanlent, a Director at Trevi Therapeutics, Inc., has been granted non-statutory stock options.
• The options are for 35,000 shares of common stock.
• The exercise price for these options is $13.45 per share.
• The grant date for these options was June 3, 2026.
• These options are scheduled to fully vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting following the grant date, provided continued service.
• The options have an expiration date of June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director rather than a significant financial event or strategic shift.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule encourages continued service and alignment with shareholder interests.

Future Outlook

The stock options are set to vest over time, contingent on continued service, and expire in 2036, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry to attract and retain talent and align executive interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard compensation practice. The long-term vesting and exercise terms aim to align director interests with shareholder value creation.
• Employees: This filing does not directly impact employees, but it reflects a common compensation strategy within the company.
• Management: Reinforces standard executive compensation practices.

Next Steps

• Anne Vanlent's continued service as Director.
• Vesting of stock options according to the defined schedule.
• Potential exercise of stock options upon vesting, subject to market conditions and personal financial planning.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Award